Instituto de Biomedicina de Sevilla -ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2017

  1. Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies

    Clinical Lung Cancer, Vol. 18, Núm. 5, pp. 489-496

2016

  1. IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF)

    Journal of Thoracic Oncology, Vol. 11, Núm. 12, pp. 2183-2192

2015

  1. Non-small-cell lung cancer: Role of the immune system and potential for immunotherapy

    Journal of Thoracic Oncology, Vol. 10, Núm. 7, pp. 974-984

2014

  1. Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis

    Lung Cancer, Vol. 85, Núm. 2, pp. 230-238

  2. Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately after Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer

    Clinical Lung Cancer, Vol. 15, Núm. 6, pp. 418-425

  3. Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC

    Journal of Cellular and Molecular Medicine, Vol. 18, Núm. 8, pp. 1519-1539

  4. VeriStrat: A prognostic and/or predictive biomarker for advanced lung cancer patients?

    Expert Review of Respiratory Medicine, Vol. 8, Núm. 1, pp. 1-4

2013

  1. Identification of oxidative stress related proteins as biomarkers for lung cancer and chronic obstructive pulmonary disease in bronchoalveolar lavage

    International Journal of Molecular Sciences, Vol. 14, Núm. 2, pp. 3440-3455

  2. Inhibidores de MET en el cáncer de pulmón

    Revisiones en Cancer

  3. Inhibition of HSP90 molecular chaperones: Moving into the clinic

    The Lancet Oncology, Vol. 14, Núm. 9

  4. Tratamiento de mantenimiento en el cáncer no microcítico de pulmón (CNMP)

    Revisiones en Cancer

2012

  1. Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies

    Disease Markers, Vol. 32, Núm. 4, pp. 221-230

  2. Beyond first-line NSCLC therapy: Chemotherapy or erlotinib?

    The Lancet Oncology

  3. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

    Clinical Cancer Research, Vol. 18, Núm. 11, pp. 3170-3179

  4. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study

    The Lancet Oncology, Vol. 13, Núm. 1, pp. 33-42

  5. Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

    Lung Cancer, Vol. 76, Núm. 3, pp. 269-279

  6. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: A phase II study evaluating co-treatment with dexamethasone

    Investigational New Drugs, Vol. 30, Núm. 2, pp. 729-740

2011

  1. Down-regulation of spinophilin in lung tumours contributes to tumourigenesis

    Journal of Pathology, Vol. 225, Núm. 1, pp. 73-82

  2. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study

    The Lancet Oncology, Vol. 12, Núm. 1, pp. 30-37

  3. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

    The Lancet Oncology, Vol. 12, Núm. 8, pp. 795-805